Focus Partners Advisor Solutions LLC Boosts Holdings in Zoetis Inc. $ZTS

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Zoetis Inc. by 67.4%, owning 4,581 shares worth approximately $754,000 after acquiring an additional 1,845 shares in the first quarter.
• Several institutional investors, including Vanguard Group and Goldman Sachs, also boosted their positions in Zoetis, reflecting high institutional ownership of 92.80% of the company's stock.
• Zoetis reported earnings of $1.76 EPS for the quarter, exceeding estimates, with revenues of $2.46 billion, marking a year-over-year growth of 4.2%.

Focus Partners Advisor Solutions LLC increased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 67.4% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 4,581 shares of the company's stock after buying an additional 1,845 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Zoetis were worth $754,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. Saudi Central Bank purchased a new stake in shares of Zoetis during the first quarter worth approximately $29,000. Cornerstone Planning Group LLC lifted its position in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the period. Sound Income Strategies LLC increased its holdings in shares of Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares in the last quarter. Finally, Bfsg LLC boosted its position in shares of Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after purchasing an additional 252 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

NYSE ZTS traded down $1.44 during trading hours on Monday, reaching $151.88. 3,263,016 shares of the company's stock were exchanged, compared to its average volume of 3,040,548. The firm has a fifty day moving average of $153.16 and a 200-day moving average of $157.73. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $67.31 billion, a PE ratio of 26.14, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the previous year, the business earned $1.56 earnings per share. Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.